Table 4.
Production conditions and results of studies published. Success is defined either as number of all eyes/patients improving or as reduction of mean baseline (as stated in the paper) of fluorescein, rose bengal positive epitheliopathy (objective), or symptoms (subjective) score
| Author | Year | Concentration/diluent | Centrifugation (g force/duration) | Clotting time | Frequency/remarks | Indication | Eyes (patients) | Success objective | Success subjective |
| Fox1 | 1984 | 33%/0.9% NaCl | 500 g/10 min | NR | 2 hourly | KCS | 30 (15) | RB 41% | 51%; 15 (15) |
| Tsubota2 | 1999 | 20%/NaCl | 1500 rpm/5 min | NR | 6–10× | KCS in SS | 24 (12) | Fl: 55 %; RB: 68% | 34 % |
| Rocha35 | 2000 | 33%/0.9% NaCl | 500 g/10 min | NR | Hourly, filtered | KCS in GVHD | 4 (2) | 4 (4) | 4 (4) |
| Poon33 | 2001 | 50–100%/0.5% chloramphenicol | 4000 rpm (2200 g)/10 min | 2 h | 8× | KCS | 11 (9) | Fl: 6 (11) BR: 5 (11) | 6 (11) |
| Tananuvat38 | 2001 | 20%/0.9% NaCl | 4200 rpm/15 min | NR | 6× | KCS | 12 (12) | Fl: 39%; RB: 33% IPC 44% | 36% (NS) |
| Takamura37 | 2002 | 20%/0.9% NaCl | 3000 rpm/10 min | NR | 4–8× | KCS | NR (26) | “improved” | 20 (26) |
| Ogawa36 | 2003 | 20%/0.9% NaCl | 1500 rpm/5 min | NR | 10× | KCS in GVHD | 28 (14) | Fl: 61%, RB 40% | 30 % |
| McDonnell47 | 1988 | 100% | NC/15–20 min | 15 min | 1–2 hourly | PED | 1 (1) | IC deposition | No |
| Tsubota25 | 1999 | 20%/NaCl | 1500 rpm/5 min | NR | 6–10× | PED | 16 (15) | 10 (16) | NR |
| Poon33 | 2001 | 50–100%/0.5% chloramphenicol | 4000 rpm (2200 g)/10 min | 2 h | 8× | PED | 15 (13) | 9 (15) | NR |
| De Souza42 | 2001 | 100% | NC | NR | Hourly | PED/PK | 70 (63) | 57 (70) | NR |
| Garcia43 | 2003 | 20%/0.9% NaCl | 5000 rpm/10 min | NR | 10× | PED | 11 (11) | 6 (11) | NR |
| Tsubota45 | 1996 | 20%/NaCl | 1500 rpm/5 min | NR | ¼ hourly | LSC-Tx, PK | 14 (11) | 12 (14) | NR |
| Poon33 | 2001 | 50–100%/0.5% chloramphenicol | 4000 rpm (2200 g)/10 min | 2 h | 8× | PK | 2 (2) | 2 (2) | NR |
| Del Castillo41 | 2002 | 20%/0.9% NaCl | 1500 rpm/5 min | NR | 3× | RES | 11 (11) | 8 (11); RoR: 99% | NR |
| Goto40 | 2001 | 20%/0.9% NaCl | 1500 rpm/5 min | NR | 10× | SLK | 22 (11) | Fl 88%, BR 91% IPC 100% | 21%, 9 (11) |
| Noble39 | 2003 | 50%/0.9% NaCl | NR | 48–72 h | Replacement | OSD | 32 (16) | IPC 9 (25) | 10 (16) |
| Matsumoto20a | 2004 | 20%/NaCl | 3000 rpm/10 min | NR | 5–10× | NK | 14 (11) | 14 (14) | NR |
Note that the scale used to measure these changes as well as the baseline level varied between the studies. GvHD, graft versus host disease; IC, immune complex; IPC, impression cytology; KCS, keratoconjunctivitis sicca; LSCTX, limbal stem cell transplautation; NK, neurotrophic keratopathy; NR, not reported; NS, not significant; OS, ocular surface; OSD, ocular surface disease; PED, persistent epithelial defect; PK, penetrating keratoplasty; Replacement, frequency equivalent to previously applied pharmaceutical tear substitute; RoR, rate of recurrence; SLK, superior limbal keratoconjunctivitis; SS, Sjögren’s syndrome.